SCILEX HOLDING COMPANY

Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia

31 May 2023 15:16:05 By Nasdaq GlobeNewswire

Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023

22 May 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain

04 May 2023 09:00:01 By Nasdaq GlobeNewswire

Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023

28 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrento’s Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend

25 Apr 2023 19:30:00 By Nasdaq GlobeNewswire

Scilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido® in the Middle East and North Africa Region

17 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders

14 Apr 2023 18:32:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders

05 Apr 2023 17:27:43 By Nasdaq GlobeNewswire

Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock

27 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products

21 Mar 2023 09:00:02 By Nasdaq GlobeNewswire

Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment

08 Mar 2023 10:13:07 By Nasdaq GlobeNewswire

Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management

27 Feb 2023 09:00:01 By Nasdaq GlobeNewswire